In addition to landing ex-Takeda cell therapy expert Dan Kemp as CEO, Wugen has now raised $172 million to advance an off-the-shelf cell therapy pipeline.
Wugen appointed Daniel Kemp, who most recently played a key role in Takeda’s oncology cell therapy leadership team, as CEO back in April. Now, the biotech is getting ready to take its therapies forward, and has just completed a round of series B financing to the tune of $172 million.
The new funding will be used to advance the company’s natural killer (NK) cell platform and take lead program WU-NK-101 for relapsed/refractory acute myelogenous leukemia (AML) through a phase I/II trial. Wugen also plans to initiate studies in other cancer indications, including solid tumors, and will put some proceeds towards a pipeline that includes an allogeneic CAR-T treatment for T-cell leukemia and lymphoma.
“We have tremendous confidence that our off-the-shelf memory NK cell platform will give rise to a significant pipeline of highly effective and safe anti-cancer therapies. In an ongoing Phase 1/2 clinical trial, our lead product WU-NK-101 has demonstrated an impressive complete response rate in relapsed/refractory AML and we look forward to advancing into a global multi-center study later this year. In parallel, we’re also pursuing solid tumor indications both as monotherapy and in combination with antibody drugs” commented Daniel Kemp in a press release.